Department of Internal Medicine, Diabetology, and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Department of Nephrology, Hypertensiology, and Internal Diseases, University of Warmia and Mazury, Olsztyn, Poland.
Endokrynol Pol. 2020;71(6):545-550. doi: 10.5603/EP.a2020.0077.
Diabetic kidney disease (DKD) remains the leading cause of the end-stage renal disease (ESRD) and the most common reason for renal replacement therapy. Research has been carried out for years to find a marker that would enable early identification of people at risk of DKD occurrence, as well as people who will progress from DKD to ESRD. With regard to daily medical practice, the only existing prognostic biomarkers in DKD remain urine albumin-creatinine ratio based on the urinary assessment of albumin and creatinine, and estimated glomerular filtration rate - on the basis of serum creatinine concentration. The development of other biomarkers that would enable the identification of patients at risk of DKD, the stratification of the risk of progression to ESRD, as well as the creation of personalised therapy is currently of great interest. This article discusses selected studies in this field, which have been published in recent years.
糖尿病肾病（DKD）仍然是终末期肾病（ESRD）的主要原因，也是肾脏替代治疗最常见的原因。多年来，一直在研究寻找一种标志物，以便能够早期识别有发生 DKD 风险的人群，以及有从 DKD 进展到 ESRD 风险的人群。在日常医疗实践中，DKD 中唯一现有的预后生物标志物仍然是基于尿液白蛋白和肌酐评估的尿白蛋白-肌酐比值，以及基于血清肌酐浓度的估计肾小球滤过率。目前，人们非常关注开发其他生物标志物，以识别有发生 DKD 风险的患者，对进展为 ESRD 的风险进行分层，并制定个体化治疗方案。本文讨论了近年来发表的该领域的一些选定研究。
